Alpha9 Theranostics

About

Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.

Vancouver,British Columbia,Canada
11 - 50
https://www.alpha9tx.com/

Highlights

Details

Last Funding Type: Series B
Last Funding Money Raised: $75M
Industries: Biotechnology,Medical,Product Research
Founded date: Jan 1, 2019
Number Of Employee: 11 - 50
Operating Status: Active
Legal Name: Alpha9 Theranostics Inc

Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies. The company is creating a strong pipeline of radiopharmaceuticals to target solid and hematologic malignancies. Its systematic approach to radiotherapeutic design is fueled by a toolbox of technologies and chemistries, which offers broad potential for expansion into a multitude of oncology targets.

Alpha9 Theranostics was founded in 2019 and is headquartered in Vancouver, Canada.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

3

$75.07M $11M

Alpha9 Theranostics has raised a total of $75.07M $11M in funding over 2 rounds. Their latest funding was raised on Dec 14, 2022 from a Series B round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Dec 14, 2022	Series B	$75M	6	Nextech Invest	—	Detail
Apr 28, 2021	Series A	$11M	2	Longitude Capital	—	Detail
Jun 30, 2020	Seed	$77K	1	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

2

7

Alpha9 Theranostics is funded by 7 investors. Nextech Invest and BVF Partners are the most recent investors.

Investor Name	Lead Investor	Funding Round
Nextech Invest	Yes	Series B
BVF Partners	—	Series B
Frazier Life Sciences	—	Series B
Longitude Capital	—	Series B
Quark Venture	—	Series B
Samsara BioCapital	—	Series B
WUTIF	—	Seed